A Phase IIa Open-label, Randomized Study to Compare the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of NM-IL-12 (rHuIL-12) to Standard of Care in Subjects With Open Surgical Wounds Following Colostomy Takedown Allowed to Heal by Secondary Intention

Trial Profile

A Phase IIa Open-label, Randomized Study to Compare the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of NM-IL-12 (rHuIL-12) to Standard of Care in Subjects With Open Surgical Wounds Following Colostomy Takedown Allowed to Heal by Secondary Intention

Recruiting
Phase of Trial: Phase II

Latest Information Update: 05 Aug 2016

At a glance

  • Drugs NMIL 12 1 (Primary)
  • Indications Wound infections
  • Focus Adverse reactions
  • Sponsors Neumedicines
  • Most Recent Events

    • 29 Dec 2015 According to ClinicalTrials.gov record, status changed from not yet recruiting to recruiting.
    • 09 Mar 2015 New trial record
    • 02 Mar 2015 Neumedicines has received a US Department of Defense Military Infectious Diseases Clinic Trial Award for this trial, according to a media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top